Monopar Therapeutics Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline

Reuters11-09

<a href="https://laohu8.com/S/MNPR">Monopar Therapeutics</a> Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline

Monopar Therapeutics Inc. announced new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study evaluating tiomolybdate choline in patients with Wilson disease. The results, which were presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2025, demonstrated that treatment with ALXN1840 led to a rapid and sustained improvement in daily copper balance, primarily through increased fecal copper excretion. The mean daily copper balance among patients treated with ALXN1840 was significantly lower compared to their pre-treatment baseline. Additional nonclinical and clinical data supporting these findings from the ALXN1840-WD-204 study were also presented at the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief on November 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2582892414?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-09 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582892414","market":"fut","top_or_hot":-1,"title":"Monopar Therapeutics Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MNPR\">Monopar Therapeutics</a> Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monopar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study evaluating tiomolybdate choline in patients with Wilson disease. The results, which were presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2025, demonstrated that treatment with ALXN1840 led to a rapid and sustained improvement in daily copper balance, primarily through increased fecal copper excretion. The mean daily copper balance among patients treated with ALXN1840 was significantly lower compared to their pre-treatment baseline. Additional nonclinical and clinical data supporting these findings from the ALXN1840-WD-204 study were also presented at the meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief on November 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monopar Therapeutics Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonopar Therapeutics Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-09 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MNPR\">Monopar Therapeutics</a> Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Monopar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. announced new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study evaluating tiomolybdate choline in patients with Wilson disease. The results, which were presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2025, demonstrated that treatment with ALXN1840 led to a rapid and sustained improvement in daily copper balance, primarily through increased fecal copper excretion. The mean daily copper balance among patients treated with ALXN1840 was significantly lower compared to their pre-treatment baseline. Additional nonclinical and clinical data supporting these findings from the ALXN1840-WD-204 study were also presented at the meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief on November 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNPR","symbol_name":"Monopar Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251109:nNDL217lBn:1","article_id":"2582892414","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582892414","pubTimestamp":1762697260,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Monopar Therapeutics Inc. announced new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study evaluating tiomolybdate choline in patients with Wilson disease. The results, which were presented at the American Association for the Study of Liver Diseases  - The Liver Meeting 2025, demonstrated that treatment with ALXN1840 led to a rapid and sustained improvement in daily copper balance, primarily through increased fecal copper excretion. The mean daily copper balance among patients treated with ALXN1840 was significantly lower compared to their pre-treatment baseline. Additional nonclinical and clinical data supporting these findings from the ALXN1840-WD-204 study were also presented at the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNPR":"Monopar Therapeutics","BK4139":"生物科技"},"translate_title":"Monopar Therapeutics报告使用硫代钼酸胆碱可快速改善Wilson病患者的铜平衡","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNPR":0.9},"content_text":"Monopar Therapeutics Reports Rapid Copper Balance Improvement in Wilson Disease Patients with Tiomolybdate Choline\n    \n\n        Monopar Therapeutics Inc. announced new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study evaluating tiomolybdate choline in patients with Wilson disease. The results, which were presented at the American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2025, demonstrated that treatment with ALXN1840 led to a rapid and sustained improvement in daily copper balance, primarily through increased fecal copper excretion. The mean daily copper balance among patients treated with ALXN1840 was significantly lower compared to their pre-treatment baseline. Additional nonclinical and clinical data supporting these findings from the ALXN1840-WD-204 study were also presented at the meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief on November 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582892414","isCrawlerRequest":true}